Advisory Committee for Immunization Practices (ACIP) recommendations for RSV vaccines for older adults!

The Centers for Disease Control and Prevention (CDC) recommends that everyone aged 75 and older receive a respiratory syncytial virus (RSV) vaccine and that adults ages 60–74 who are at increased risk of severe RSV disease also receive the vaccine. On April 16, 2025, the ACIP voted unanimously to lower the recommendation for those adults who are at increased risk of severe RSV disease to those aged 50 and older. NANASP has been a consistent advocate for lowering the recommendation for adult RSV vaccines down to age 50 so this is a welcome change. The CDC is expected to finalize this recommendation in the near future.

RSV vaccines act as a safeguard, significantly reducing the risk and severity of respiratory infections. The RSV vaccine is not currently an annual vaccine and can be administered at any time during the year, and at the same time as other vaccines. Discuss the vaccine with your healthcare provider to assess its relevance to your health. Stay informed and prioritize preventive measures to ensure a resilient and healthy golden phase. Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV.

Did you know? 

RSV vaccines are completely covered by Medicare and many private insurances?